CYP3A4 breaks down drugs that treat various health conditions, including the anti-cancer agent paclitaxel and COVID-19 therapeutic nirmatrelvir. CYP3A4 inhibitors are commonly co-administered to ...

Some medications and supplements can make your birth control less effective at preventing pregnancy. These include some ...

The FDA has updated the labeling for Camzyos to reduce echocardiogram monitoring requirements for patients in the maintenance phase and contraindications.

FDA approves Camzyos label update easing echo monitoring and lifting drug interaction limits, supported by 3.5 years of safety data and real-world use ...

Label updates include simplified twice-yearly echo monitoring for eligible CAMZYOS patients in the maintenance phase and expanded patient eligibility with reduced contraindication ...

The simplified requirements for Camzyos are expected to ease prior contraindications, thereby simplifying treatment and ...